Complex antiphospholipid syndrome successfully controlled for 17 years with personalized enoxaparin therapy

This patient presented with rare manifestations of antiphospholipid syndrome (APS), such as acalculous cholecystitis, Budd-Chiari syndrome, and Addison's disease, all linked to ischemic events caused by vascular thrombosis. These atypical presentations highlight the varied and severe clinical spectrum of APS, requiring physicians to be vigilant about unusual complications.After multiple severe thrombotic and haemorrhagic events, the patient was successfully managed with long-term enoxaparin, with dose adjusted according to anti-factor Xa activity (which allowed for a significant dose reduction in comparison with the predicted empiric dose).The patient remained event-free for 17 years, reflecting the importance of personalizing anticoagulation therapy.

Authors

Institutions

Publication Details

Journal
European Journal of Case Reports in Internal Medicine
Published
2024-10-24
DOI
https://doi.org/10.12890/2024_004877
Primary Topic
Systemic Lupus Erythematosus Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Complex antiphospholipid syndrome successfully controlled for 17 years with personalized enoxaparin therapy

Carla Noronha, Mafalda Vasconcelos, Patrícia Pinatti Moreira, Teresa Costa e Silva et al.
European Journal of Case Reports in Internal Medicine
Systemic Lupus Erythematosus Research
article

Complex antiphospholipid syndrome successfully controlled for 17 years with personalized enoxaparin therapy

Carla Noronha, Mafalda Vasconcelos, Patrícia Pinatti Moreira, Teresa Costa e Silva, João Espírito Santo
article en

Abstract

This patient presented with rare manifestations of antiphospholipid syndrome (APS), such as acalculous cholecystitis, Budd-Chiari syndrome, and Addison's disease, all linked to ischemic events caused by vascular thrombosis. These atypical presentations highlight the varied and severe clinical spectrum of APS, requiring physicians to be vigilant about unusual complications.After multiple severe thrombotic and haemorrhagic events, the patient was successfully managed with long-term enoxaparin, with dose adjusted according to anti-factor Xa activity (which allowed for a significant dose reduction in comparison with the predicted empiric dose).The patient remained event-free for 17 years, reflecting the importance of personalizing anticoagulation therapy.

European Journal of Case Reports in Internal MedicineVol. 11(11)
Hospital Beatriz Ângelo (PT)
Good health and well-being
Openalex Percentile: Top 67%
Systemic Lupus Erythematosus Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Complex antiphospholipid syndrome successfully controlled for 17 years with personalized enoxaparin therapy — Carla Noronha, Mafalda Vasconcelos, et al. · European Journal of Case Reports in Internal Medicine (2024) | TGRS Research Map | TGRS